Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2019
Shenzhen Stock Exchange terminates Changsheng Bio-technology’s listing
Ban or restriction
On October 8, 2019, the Shenzhen Stock Exchange decided to terminate the listing of Changsheng Bio-Technology’s shares after finding that the company met the criteria for mandatory delisting for major violations. The shares were scheduled to enter the delisting consolidation period on October 16.
Source excerpt
长生生物因触及《深圳证券交易所上市公司重大违法强制退市实施办法》第二条、第五条规定的重大违法强制退市情形
2019年10月8日，深交所决定公司股票终止上市，并自2019年10月16日起进入退市整理期
2018
Changsheng vaccine scandal
Authorities uncovered falsified rabies-vaccine production data, ineffective DPT vaccines administered to children, alleged bribery involving a sales representative, and violations of securities-disclosure rules. The investigation resulted in large fines, executive bans, criminal proceedings, revocation of production authorization and the company's eventual bankruptcy.
2018
License revoked for illegal rabies vaccine production, fined and confiscated about 9.1 billion yuan
In 2018, drug regulators determined that Changsheng Bio-Technology illegally produced rabies vaccines in violation of regulations, revoked its approval documents and batch release certificates, and revoked its production license; Jilin authorities imposed fines and confiscations of about 9.1 billion yuan, and the responsible executives were banned from the industry. This entry completes the original vaccine scandal and final administrative disposition without fabricating a criminal judgment against Gao Junfang.